Replicel Life Sciences Overview
- Year Founded
-
1967
- Status
-
Public
- Employees
-
6
- Stock Symbol
-
RP
- Investments
-
3
- Share Price
-
$0.04
- (As of Thursday Closing)
Replicel Life Sciences General Information
Description
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from the Licensing fees.
Contact Information
Website
www.replicel.comCorporate Office
- 570 Granville Street
- Suite 900
- Vancouver, British Columbia V6C 3P1
- Canada
Corporate Office
- 570 Granville Street
- Suite 900
- Vancouver, British Columbia V6C 3P1
- Canada
Replicel Life Sciences Timeline
Replicel Life Sciences Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.04 | $0.04 | $0.03 - $0.19 | $2.65M | 65M | 24.5K | -$0.01 |
Replicel Life Sciences Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 5,296 | 2,640 | 6,718 | 6,028 |
| Revenue | 262 | 271 | 282 | 264 |
| EBITDA | (49) | (565) | (3,242) | (1,177) |
| Net Income | (51) | (570) | (3,248) | (1,178) |
| Total Assets | 244 | 588 | 464 | 330 |
| Total Debt | 30 | 30 | 27 | 60 |
Replicel Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Replicel Life Sciences Comparisons
Industry
Financing
Details
Replicel Life Sciences Competitors (68)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sernova | Corporation | London, Canada | ||||
| PolarityTE | Corporate Backed or Acquired | Salt Lake City, UT | ||||
| Regenerative Medical Solutions | Venture Capital-Backed | Madison, WI | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Orgenesis | Corporation | Germantown, MD |
Replicel Life Sciences Patents
Replicel Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3237451-A1 | Injection devices | Pending | 11-Nov-2021 | ||
| EP-4429739-A1 | Injection devices | Pending | 11-Nov-2021 | ||
| US-11045612-B2 | Injection devices | Active | 06-Aug-2014 | ||
| EP-3177348-A1 | Injection devices | Pending | 06-Aug-2014 | ||
| AU-2020202425-A1 | Injection devices | Inactive | 06-Aug-2014 | A61M5/44 |
Replicel Life Sciences Executive Team (7)
| Name | Title | Board Seat |
|---|---|---|
| Andrew Schutte | President, Chief Executive Officer & Board Member | |
| David Kwok | Chief Financial Officer | |
| Ben Austring | Chief Operating Officer, Operations & Secretary, Administration | |
| Kevin McElwee Ph.D | Chief Scientific Officer & Founder | |
| Rolf Hoffmann MD | Chief Medical Officer |
Replicel Life Sciences Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Replicel Life Sciences | President, Chief Executive Officer & Board Member | ||
| Self | Chairman & Board Member | ||
| Self | Independent Director |
Replicel Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Replicel Life Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Replicel Life Sciences Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TrichoScience Innovations | 09-May-2011 | Other Healthcare Services | |||
| 583885 B.C. | 23-Dec-2010 | Consulting Services (B2B) | |||
| Newcastle Resources | 22-Dec-2010 | Merger/Acquisition | Biotechnology |
Replicel Life Sciences FAQs
-
When was Replicel Life Sciences founded?
Replicel Life Sciences was founded in 1967.
-
Who is the founder of Replicel Life Sciences?
Kevin McElwee Ph.D and Rolf Hoffmann MD are the founders of Replicel Life Sciences.
-
Who is the CEO of Replicel Life Sciences?
Andrew Schutte is the CEO of Replicel Life Sciences.
-
Where is Replicel Life Sciences headquartered?
Replicel Life Sciences is headquartered in Vancouver, Canada.
-
What is the size of Replicel Life Sciences?
Replicel Life Sciences has 6 total employees.
-
What industry is Replicel Life Sciences in?
Replicel Life Sciences’s primary industry is Drug Discovery.
-
Is Replicel Life Sciences a private or public company?
Replicel Life Sciences is a Public company.
-
What is Replicel Life Sciences’s stock symbol?
The ticker symbol for Replicel Life Sciences is RP.
-
What is the current stock price of Replicel Life Sciences?
As of 14-Mar-2024 the stock price of Replicel Life Sciences is $0.04.
-
What is the current market cap of Replicel Life Sciences?
The current market capitalization of Replicel Life Sciences is $2.65M.
-
What is Replicel Life Sciences’s current revenue?
The trailing twelve month revenue for Replicel Life Sciences is $262K.
-
Who are Replicel Life Sciences’s competitors?
Sernova, PolarityTE, Regenerative Medical Solutions, Mesoblast, and Orgenesis are some of the 68 competitors of Replicel Life Sciences.
-
What is Replicel Life Sciences’s annual earnings per share (EPS)?
Replicel Life Sciences’s EPS for 12 months was -$0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
